In what could be the biggest medtech deal of the year so far, the boards of Hologic (Bedford, Massachusetts) and Gen-Probe (San Diego) have approved an agreement under which Hologic would acquire all of the outstanding shares of Gen-Probe for $82.75 a share in cash, or a total enterprise value of about $3.7 billion. Read More
